Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative disorders that affects the basal ganglia and the motor system (parkinsonism), autonomic nervous system (dysautonomia ...

Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American ...

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –– Topline Data Expected Mid-Year 2025 –MELBOURNE, Australia and ...

Opens in a new tab or window A machine learning model differentiated Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. AUROCs and predictive values for ...

Nitrated α-synuclein is upregulated in the CSF of patients with Parkinson’s Disease (PD), Lewy body dementia (DLB), multiple system atrophy (MSA), and other synucleinopathies.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced promising new data from its Phase 2 trial of ATH434 in Multiple ...

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease< ...

Multiple system atrophy (MSA) is a progressive disorder of the nervous system. The neurodegenerative disease is characterized by symptoms that affect movement and the autonomic nervous system.

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...